Table 3 Response rates and proportion of patients with measured tumor shrinkage >10% in single agent placebo or best supportive care arms of randomized trials
From: Fool’s gold, lost treasures, and the randomized clinical trial
Tumor type | RECIST response % | % of patients with measurable tumor shrinkage >10%a |
|---|---|---|
NSCLC [21] | 1 | NAb |
NSCLC [22] | <1 | NA |
NSCLC [91] | 0.7 | NA |
NSCLC [92] | 1 | NA |
Colorectal [52] | 0 | 1 |
Colorectal [93] | 0 | NA |
Colorectal [94] | 0 | NA |
Renal cell [95] | 2 | NA |
Renal cell [96] | 0 | NA |
Renal cell [97] | 3 | NA |
Renal cell [98] | 0 | 4 |
Renal cell [99] | 0 | 5.5 |
Hepatocellular [100] | 0 | 9 |
Hepatocellular [101] | 3 | NA |
Hepatocellular [102] | 1.3 | NA |
Head and neck cancer [103] | 0 | 7 |
Head and neck cancer [104] | 1 | NA |
Head and neck cancer [105] | 3 | NA |
Transitional cell [106] | 0 | NA |
Pancreatic neuroendocrine [107] | 0 | 7 |
Pancreatic neuroendocrine [112] | 2 | 6.6 |
Prostate [108] | 4 | NA |
Sarcoma [109] | 0 | NA |
Medullary thyroid [110] | 1 | NA |
Mesothelioma [111] | 1.7 | NA |